Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 22 (66.7%)
Phase 41 (33.3%)

Trials by Status

recruiting133%
not_yet_recruiting267%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Local Injection and Systemic Therapy in the Treatment of NSCLC.

NCT06618391
not_yet_recruitingphase_2

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

NCT06253598
recruitingphase_4

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

NCT05124002

Clinical Trials (3)

Showing 3 of 3 trials
NCT06618391Phase 2

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Not Yet Recruiting
NCT06253598Phase 2

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Not Yet Recruiting
NCT05124002Phase 4

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3